Fund shareholders of FIBROBIOLOGICS INC
ISIN US31573L2043 · United States · LEI 5493000KQEGHXVWRMZ92
- Fund shareholders
- 5
- Of which ETFs
- 0 5 other funds
- Value held
- 55.9K $
- Share of capital
- 0.8 % of 6.7M shares on Jul 31, 2026
This issuer has other securities: FIBROBIOLOGICS INC (US31573L1052)
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 27,769 | 26.3K $ | 0.42 % | as of Jun 30, 2026 ↗ | |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 19,544 | 22.7K $ | 0.00 % | 0.29 % | as of May 31, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 2,571 | 3K $ | 0.04 % | as of May 31, 2026 ↗ | |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 2,266 | 2.6K $ | 0.03 % | as of May 31, 2026 ↗ | |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 1,099 | 1.3K $ | 0.02 % | as of May 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of May 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 5 | +1 | 53,249 | -28.2 % |
| 2026Q2 | 4 | 74,116 |
Institutional managers
13 managers declare this company to the SEC (Form 13F).
| Manager | Shares | Value | |
|---|---|---|---|
| Fund Evaluation Group, LLC | 51,794 | 68.4K $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 29,609 | 39.1K $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 24,647 | 32.5K $ | as of Mar 31, 2026 |
| Cascade Financial Partners, LLC | 16,428 | 21.7K $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 15,997 | 21.1K $ | as of Mar 31, 2026 |
| UBS Group AG | 5,721 | 7.6K $ | as of Mar 31, 2026 |
| Tower Research Capital LLC (TRC) | 460 | 607 $ | as of Mar 31, 2026 |
| Western Wealth Management, LLC | 200 | 264 $ | as of Mar 31, 2026 |
| ISLAY CAPITAL MANAGEMENT, LLC | 169 | 223 $ | as of Mar 31, 2026 |
| OSAIC HOLDINGS, INC. | 154 | 203 $ | as of Mar 31, 2026 |
| BNP PARIBAS FINANCIAL MARKETS | 66 | 87 $ | as of Mar 31, 2026 |
| Allworth Financial LP | 13 | 18 $ | as of Mar 31, 2026 |
| WELLS FARGO & COMPANY/MN | 10 | 13 $ | as of Mar 31, 2026 |
Declared shareholders of FIBROBIOLOGICS INC
There are 2 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Armistice Capital, LLC and 1 other | 9.99 % | 738,977 | as of Jun 30, 2026 · SCHEDULE 13G |
| Hamid Khoja | 7.50 % | 630,009 | as of Sep 15, 2026 · SCHEDULE 13D |
Cite this page
Titelia. "Fund shareholders of FIBROBIOLOGICS INC". https://titelia.com/en/stocks/fibrobiologics-inc-US31573L2043